Based on the results of preclinical studies, future randomized clinical trials should be designed to evaluate vitamin C activity in specific tumor molecular subtypes, such as those characterized by HIF-1α over-expression and TET2, L2HGDH, IDH1/2, or WT1 altered pathways [194]. The gene discussed is L2HGDH; the disease is neoplasm.